High cost of cancer care in the U.S. doesn't reduce mortality rates
- Details
- Category: Research
While the U.S. spends twice as much on cancer care as the average high-income country, its cancer mortality rates are only slightly better than average, according to a new analysis by researchers at Yale University and Vassar College.
The results were published May 27 in JAMA Health Forum.
Medicare program spent $1.8 billion in 2019 on drugs without confirmed clinical benefits
- Details
- Category: Research
The U.S. federal government spent an estimated $1.8 billion in Medicare funds in 2019 on drugs whose clinical benefits have yet to be confirmed by the Food and Drug Administration, a new study led by researchers from the Johns Hopkins Bloomberg School of Public Health suggests.
Scientists find sea corals are source of sought-after "anti-cancer" compound
- Details
- Category: Research
The bottom of the ocean is full of mysteries but scientists have recently uncovered one of its best-kept secrets. For 25 years, drug hunters have been searching for the source of a natural chemical that had shown promise in initial studies for treating cancer. Now, researchers at University of Utah Health report that easy-to-find soft corals - flexible corals that resemble underwater plants - make the elusive compound.
Study identifies new molecular target for cancer therapy
- Details
- Category: Research
Researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) have identified a new molecular drug target that could result in new cancer drugs with fewer side effects.
Previous studies have shown that vascular endothelial growth factor-A (VEGF-A) - a potent cytokine (signaling protein) - and dopamine (a neurotransmitter/neurohormone) play essential roles in many physiological and pathological functions.
"Natural immunity" from omicron is weak and limited, study finds
- Details
- Category: Research
In unvaccinated people, infection with the Omicron variant of SARS-CoV-2 provides little long-term immunity against other variants, according to a new study by researchers at Gladstone Institutes and UC San Francisco (UCSF), published today in the journal Nature.
In experiments using mice and blood samples from donors who were infected with Omicron, the team found that the Omicron variant induces only a weak immune response.
mRNA booster vaccines may be a good investment in developing countries
- Details
- Category: Research
Vaccines based on inactivated SARS-CoV-2 virus are commonly used in developing countries due to their low cost. New research from Karolinska Institutet in Sweden shows that a booster shot of mRNA vaccine to individuals who have received two doses of inactivated vaccine offers the same level of protection against COVID-19 as three doses of mRNA vaccine.
Blocking spike captors to counter COVID
- Details
- Category: Research
Despite the effectiveness of vaccination campaigns worldwide, the threat posed by COVID-19 still exists. First of all, a new SARS-CoV-2 variant could very well emerge that may not respond to current vaccines. Secondly, the efficacy of the vaccines in the long term remains unknown. Lastly, cases of acute infection are continuing to be reported. And yet, there is no effective treatment to date.
More Pharma News ...
- Recurring brain tumor growth is halted with new drug
- Investigational COVID mucosal vaccine protects against disease and transmission
- Using AI to analyze large amounts of biological data
- Cognitive impairment from severe COVID-19 equivalent to 20 years of ageing, study finds
- Findings open way for personalised MS treatment
- A smarter way to develop new drugs
- Asthma drug can block crucial SARS-CoV-2 protein